Private Equity's $4.2 Billion Dental Bet Is Getting Nervous

Private Equity's $4.2 Billion Dental Bet Is Getting Nervous

PE firms dropped $4.2 billion on dental deals in the first half of 2025. That's a 34% increase from last year. But here's what they're not talking about: three major portfolio companies missed 2024 revenue targets. When growth stalls, multiples compress.

You care because this affects practice valuations. If PE slows down acquisitions due to portfolio underperformance, your exit multiple shrinks. Buyers get picky. They want proof of EBITDA, not promises.

The play? If you're selling, sell while multiples are still inflated. If you're staying independent, this is your moment to acquire distressed DSO platforms at lower prices.